TY - JOUR
T1 - H3K9 histone acetylation predicts pluripotency and reprogramming capacity of ES cells
AU - Hezroni, Hadas
AU - Tzchori, Itai
AU - Davidi, Anna
AU - Mattout, Anna
AU - Biran, Alva
AU - Nissim-Rafinia, Malka
AU - Westphal, Heiner
AU - Meshorer, Eran
N1 - Funding Information: The authors would like to thank Asher Meshorer for histopathological analyses and Evgenia Leikina for technical assistant with the fusion protocols and for helpful comments. This work was supported by funds from the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development/NIH/HHS, the Israel Science Foundation (215/07 and 943/09) (to E.M.); the Israel Ministry of Health (6007) (to E.M.), the EU (IRG-206872 and 238176) (to E.M.), the ICRF (to A.M. and E.M.), The HUJI Internal Applicative Medical Grants (to E.M.), the Israeli Psychobiology Institute (to E.M.) and an Alon Fellowship (to E.M.). E.M. is a Joseph H. and Belle R. Braun Senior Lecturer in Life Sciences. H.H. is an Edmond J. Safra Fellow.
PY - 2011
Y1 - 2011
N2 - The pluripotent genome is characterized by unique epigenetic features and a decondensed chromatin conformation. However, the relationship between epigenetic regulation and pluripotency is not altogether clear. Here, using an enhanced MEF/ESC fusion protocol, we compared the reprogramming potency and histone modifications of different embryonic stem cell (ESC) lines (R1, J1, E14, C57BL/6) and found that E14 ESCs are significantly less potent, with significantly reduced H3K9ac levels. Treatment of E14 ESCs with histone deacetylase (HDAC) inhibitors (HDACi) increased H3K9ac levels and restored their reprogramming capacity. Microarray and H3K9ac ChIP-seq analyses, suggested increased extracellular matrix (ECM) activity following HDACi treatment in E14 ESCs. These data suggest that H3K9ac may predict pluripotency and that increasing pluripotency by HDAC inhibition acts through H3K9ac to enhance the activity of target genes involved in ECM production to support pluripotency.
AB - The pluripotent genome is characterized by unique epigenetic features and a decondensed chromatin conformation. However, the relationship between epigenetic regulation and pluripotency is not altogether clear. Here, using an enhanced MEF/ESC fusion protocol, we compared the reprogramming potency and histone modifications of different embryonic stem cell (ESC) lines (R1, J1, E14, C57BL/6) and found that E14 ESCs are significantly less potent, with significantly reduced H3K9ac levels. Treatment of E14 ESCs with histone deacetylase (HDAC) inhibitors (HDACi) increased H3K9ac levels and restored their reprogramming capacity. Microarray and H3K9ac ChIP-seq analyses, suggested increased extracellular matrix (ECM) activity following HDACi treatment in E14 ESCs. These data suggest that H3K9ac may predict pluripotency and that increasing pluripotency by HDAC inhibition acts through H3K9ac to enhance the activity of target genes involved in ECM production to support pluripotency.
KW - Chromatin plasticity
KW - Embryonic stem cells
KW - Histone acetylation
KW - Histone modifications
UR - http://www.scopus.com/inward/record.url?scp=80053924587&partnerID=8YFLogxK
U2 - 10.4161/nucl.2.4.16767
DO - 10.4161/nucl.2.4.16767
M3 - مقالة
C2 - 21941115
SN - 1949-1034
VL - 2
SP - 300
EP - 309
JO - Nucleus
JF - Nucleus
IS - 4
ER -